欧林生物召开2025年半年度业绩说明会 疫苗研发管线进展引关注

Core Viewpoint - The company, Chengdu Olin Biological Technology Co., Ltd., is focusing on enhancing its market position through medical education and product promotion while advancing its vaccine research and clinical trials for Staphylococcus aureus and influenza vaccines [1][2]. Financial Performance - In the first half of 2025, the company achieved a revenue of 306 million yuan, representing a year-on-year growth of 35.17% [1]. - The net profit attributable to shareholders was 13.2 million yuan, with a net profit of 7.72 million yuan after deducting non-recurring gains and losses, marking a turnaround from losses in the previous year [1]. R&D Pipeline - The company is focusing on two strategic directions: "super bacteria" vaccines and "adult vaccines," continuously enriching its pipeline and enhancing innovation capabilities [2]. - The company is researching four "super bacteria" vaccines, including recombinant Staphylococcus aureus vaccine, oral recombinant Helicobacter pylori vaccine, recombinant Pseudomonas aeruginosa vaccine, and recombinant Acinetobacter baumannii protein vaccine, all classified as global Class 1 new drugs [2]. Clinical Trials - The recombinant Staphylococcus aureus vaccine has completed Phase I and II clinical trials, with Phase III trials currently ongoing and leading globally [2]. - The vaccine aims to prevent Staphylococcus aureus infections post-surgery, with no similar products available globally, indicating a broad application potential in hospital infection prevention [3]. - The company’s Helicobacter pylori vaccine received Phase I clinical trial approval in Australia in 2024, and further optimization of the oral formulation is underway for future domestic clinical trial applications [3]. Technological Advancements - The company is expanding its technological platforms and has made significant progress in the field of viral vaccines, having initiated Phase I clinical trials for trivalent and quadrivalent influenza virus split vaccines in the first half of 2025 [3].